Barclays Issues Pessimistic Forecast for Omada Health (NASDAQ:OMDA) Stock Price

Omada Health (NASDAQ:OMDA) had its price target reduced by equities researchers at Barclays from $24.00 to $22.00 in a report released on Friday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 38.79% from the company’s current price.

Other equities analysts have also issued reports about the company. Citizens Jmp raised their price target on Omada Health from $27.00 to $32.00 and gave the stock a “market outperform” rating in a report on Friday, August 14th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Omada Health in a research note on Friday, September 11th. Weiss Ratings cut Omada Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, October 8th. Canaccord Genuity Group raised their target price on Omada Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Finally, Citigroup restated an “outperform” rating on shares of Omada Health in a research note on Friday, August 14th. Eleven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $26.33.

Omada Health Stock Down 16.4%

OMDA traded down $3.10 on Friday, hitting $15.85. The company’s stock had a trading volume of 1,829,693 shares, compared to its average volume of 1,254,319. Omada Health has a 12 month low of $10.28 and a 12 month high of $25.45. The firm has a market cap of $970.40 million, a P/E ratio of 317.10 and a beta of 2.13. The company’s 50 day simple moving average is $20.33 and its 200-day simple moving average is $17.74.

Omada Health (NASDAQ:OMDA) last issued its earnings results on Thursday, November 5th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.08. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. The business had revenue of $91.31 million for the quarter. Equities analysts predict that Omada Health will post 0.09 earnings per share for the current fiscal year.

Insider Activity

In other Omada Health news, President Wei-Li Shao sold 4,036 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.85, for a total value of $88,186.60. Following the completion of the transaction, the president directly owned 295,313 shares of the company’s stock, valued at $6,452,589.05. This trade represents a 1.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Steven L. Cook sold 6,800 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.86, for a total transaction of $148,648.00. Following the transaction, the chief financial officer owned 173,906 shares of the company’s stock, valued at $3,801,585.16. This trade represents a 3.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 106,070 shares of company stock worth $2,462,621. Insiders own 6.38% of the company’s stock.

Institutional Investors Weigh In On Omada Health

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in Omada Health during the second quarter valued at $48,775,000. Jefferies Financial Group Inc. bought a new position in Omada Health in the 2nd quarter worth about $15,016,000. Madryn Asset Management LP bought a new position in Omada Health in the 2nd quarter worth about $12,814,410. Walleye Capital LLC purchased a new stake in shares of Omada Health in the 2nd quarter valued at about $11,648,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Omada Health by 173.9% in the 1st quarter. Renaissance Technologies LLC now owns 391,069 shares of the company’s stock valued at $4,916,000 after acquiring an additional 248,269 shares in the last quarter.

Key Headlines Impacting Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Revenue rose 34% year over year to $91 million, and total members grew 36% to a record 1.1 million. Omada also reported $7 million in net income versus a year-ago loss, higher gross margins, and $12 million in adjusted EBITDA. The company raised its full-year 2026 financial outlook. Omada Health Reports Third Quarter 2026 Results
• Positive Sentiment: Quarterly earnings and revenue exceeded analyst estimates, reinforcing the company’s improving operating performance. Q3 Earnings and Revenues Beat Estimates
• Neutral Sentiment: Wells Fargo lowered its price target from $22 to $19 and maintained an equal-weight rating. The new target remains above the quoted share price, but the reduction signals more restrained expectations. Wells Fargo Recommendations
• Negative Sentiment: Zacks Research downgraded Omada from “strong buy” to “hold,” adding to the cautious analyst signals despite the earnings beat. Tickerreport coverage

About Omada Health

Omada Health, Inc (NASDAQ: OMDA) is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines personalized health coaching, clinical support, behavioral-change tools and connected devices to help members monitor and improve their health.

The company’s offerings focus primarily on cardiometabolic conditions, including diabetes, prediabetes, hypertension and obesity, as well as musculoskeletal conditions. Depending on the program, members may receive access to digital lessons, health tracking, remote monitoring, care teams and clinical guidance through Omada’s technology platform.

Omada Health was founded in 2011 and serves employers, health plans and other healthcare organizations in the United States.